Thermo Fisher Scientific (TMO) is a US-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of
94.7B, trading at $523.79 on the NYSE. This SniperIQ fundamentals page covers Thermo Fisher Scientific's valuation (P/E 28.7x, P/B 3.8x), profitability (net margin 15.2%), revenue ($44.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market Cap
94.7B
P/E (TTM)28.7x
Net Margin15.2%
Revenue (FY25)$44.6B
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is Thermo Fisher Scientific's market cap?
Thermo Fisher Scientific (TMO) has a market capitalization of approximately
94.7B, trading at $523.79 on the NYSE. Market cap moves with the live share price.
What is Thermo Fisher Scientific's P/E ratio?
Thermo Fisher Scientific's trailing twelve-month P/E ratio is 28.7x, with a price-to-book (P/B) of 3.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Thermo Fisher Scientific?
Thermo Fisher Scientific runs a net profit margin of 15.2%, a gross margin of 39.4%, and an operating margin of 17.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Thermo Fisher Scientific generate?
Thermo Fisher Scientific reported revenue of $44.6B for fiscal year 2025, with net income of $6.7B and earnings per share (EPS) of 17.77. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Thermo Fisher Scientific pay a dividend?
Thermo Fisher Scientific offers a trailing dividend yield of about 0.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Thermo Fisher Scientific financially healthy?
Thermo Fisher Scientific carries a debt-to-equity ratio of 0.83x and a current ratio of 1.53x, with a market beta of 0.87. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Thermo Fisher Scientific a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Thermo Fisher Scientific (TMO) the key facts are: market cap
94.7B, P/E 28.7x, revenue $44.6B, 52-week range 435.27-643.99. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Thermo Fisher Scientific's full fundamentals live
Get Thermo Fisher Scientific's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.